Completed PHASE3 INTERVENTIONAL 1-arm NCT00143130

Pregabalin In Partial Seizures Extension Study (PREPS EXT)

Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Seizures

Interventions Pregabalin

Updated 7 times since 2017 Last updated: Jan 26, 2021 Started: Apr 30, 2005 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Seizures and is currently completed. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Feb 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bayonne, France , Bordeaux, France , Braga, Portugal , Bruges, Belgium , Brussels, Belgium , Coimbra, Portugal , Duffel, Belgium , Funchal, Portugal , Ghent, Belgium , Grenoble, France and 30 more locations